Therapeutic strategy to rescue mutation-induced exon skipping in rhodopsin by adaptation of U1 snRNA (Human Mutation DOI: 10.1002/humu.20861);Therapeutic strategy to rescue mutation-induced exon skipping in rhodopsin by adaptation of U1 snRNA

Human Mutation

Volumn 30, Issue 2, 2009, Pages 255-263

  Tanner, Gaby ^a   Glaus, Esther ^a   Barthelmes, Daniel ^b   Ader, Marius ^c,d   Fleischhauer, Johannes ^b   Pagani, Franco ^e   Berger, Wolfgang ^a   Neidhardt, John ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

^c TRINITY COLLEGE DUBLIN   (Ireland)

^d DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^e INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Italy)

Author keywords

Retinitis pigmentosa; RHO; Rhodopsin; RP; Splice site mutation; Therapeutic strategy; Therapy; U1 snRNA

Indexed keywords

NUCLEOTIDE; RHODOPSIN; SMALL NUCLEAR RNA;

ADULT; ARTICLE; CONTROLLED STUDY; EXON; GENE MUTATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; RETINITIS PIGMENTOSA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA SPLICING;

EID: 59749104368     PISSN: 10597794     EISSN: None     Source Type: Journal    
DOI: 10.1002/humu.20943     Document Type: Erratum

References (50)

1. Bainbridge JW, Smith AJ, Barker SS, Robbie S, Henderson R, Balaggan K, Viswanathan A, Holder GE, Stockman A, Tyler N, Petersen-Jones S, Bhattacharya SS, Thrasher AJ, Fitzke FW, Carter BJ, Rubin GS, Moore AT, Ali RR. 2008. Effect of gene therapy on visual function in Leber's congenital amaurosis. N Engl J Med 358:2231-2239.
2. Baralle D, Baralle M. 2005. Splicing in action: assessing disease causing sequence changes. J Med Genet 42:737-748.
3. Bell C, Converse CA, Hammer HM, Osborne A, Haites NE. 1994. Rhodopsin mutations in a Scottish retinitis pigmentosa population, including a novel splice site mutation in intron four. Br J Ophthalmol 78:933-938.
4. Borensztajn K, Sobrier ML, Duquesnoy P, Fischer AM, Tapon-Bretaudiere J, Amselem S. 2006. Oriented scanning is the leading mechanism underlying 5′ splice site selection in mammals. PLoS Genet 2:e138.
5. Buratti E, Baralle FE. 2004. Influence of RNA secondary structure on the pre-mRNA splicing process. Mol Cell Biol 24:10505-10514.
6. Buratti E, Baralle M, Baralle FE. 2006. Defective splicing, disease and therapy: searching for master checkpoints in exon definition. Nucleic Acids Res 34:3494-3510.
7. Chen H, Chen Y, Horn R, Yang Z, Wang C, Turner MJ, Zhang K. 2006. Clinical features of autosomal dominant retinitis pigmentosa associated with a Rhodopsin mutation. Ann Acad Med Singapore 35:411-415.
8. Church DM, Stotler CJ, Rutter JL, Murrell JR, Trofatter JA, Buckler AJ. 1994. Isolation of genes from complex sources of mammalian genomic DNA using exon amplification. Nat Genet 6:98-105.
9. den Dunnen JT, Antonarakis SE. 2000. Mutation nomenclature extensions and suggestions to describe complex mutations: a discussion. Hum Mutat 15:7-12.
10. Deretic D, Williams AH, Ransom N, Morel V, Hargrave PA, Arendt A. 2005. Rhodopsin C terminus, the site of mutations causing retinal disease, regulates trafficking by binding to ADP-ribosylation factor 4 (ARF4). Proc Natl Acad Sci USA 102:3301-3306.
11. Dou Y, Fox-Walsh KL, Baldi PF, Hertel KJ. 2006. Genomic splice-site analysis reveals frequent alternative splicing close to the dominant splice site. RNA 12:2047-2056.
12. Farrar GJ, Kenna PF, Humphries P. 2002. On the genetics of retinitis pigmentosa and on mutation-independent approaches to therapeutic intervention. EMBO J 21:857-864.
13. Faustino NA, Cooper TA. 2003. Pre-mRNA splicing and human disease. Genes Dev 17:419-437.
14. Garcia-Blanco MA. 2006. Alternative splicing: therapeutic target and tool. Prog Mol Subcell Biol 44:47-64.
15. Gerber DM, Munier FL, Niemeyer G. 2003. Cross-sectional study of visual acuity and electroretinogram in two types of dominant drusen. Invest Ophthalmol Vis Sci 44:493-496.
16. Hartong DT, Berson EL, Dryja TP. 2006. Retinitis pigmentosa. Lancet 368: 1795-1809.
17. Hitomi Y, Sugiyama K, Esumi H. 1998. Suppression of the 50 splice site mutation in the Nagase analbuminemic rat with mutated U1snRNA. Biochem Biophys Res Commun 251:11-16.
18. Kennan A, Aherne A, Humphries P. 2005. Light in retinitis pigmentosa. Trends Genet 21:103-110.
19. Kiang AS, Palfi A, Ader M, Kenna PF, Millington-Ward S, Clark G, Kennan A, O'Reilly M, Tam LC, Aherne A, McNally N, Humphries P, Farrar GJ. 2005. Toward a gene therapy for dominant disease: validation of an RNA interference-based mutation-independent approach. Mol Ther 12:555-561.
20. Krawczak M, Thomas NS, Hundrieser B, Mort M, Wittig M, Hampe J, Cooper DN. 2007. Single base-pair substitutions in exon-intron junctions of human genes: nature, distribution, and consequences for mRNA splicing. Hum Mutat 28:150-158.
21. Liang FQ, Dejneka NS, Cohen DR, Krasnoperova NV, Lem J, Maguire AM, Dudus L, Fisher KJ, Bennett J. 2001. AAV-mediated delivery of ciliary neurotrophic factor prolongs photoreceptor survival in the rhodopsin knockout mouse. Mol Ther 3:241-248.
22. Liang Y, Fotiadis D, Maeda T, Maeda A, Modzelewska A, Filipek S, Saperstein DA, Engel A, Palczewski K. 2004. Rhodopsin signaling and organization in heterozygote rhodopsin knockout mice. J Biol Chem 279:48189-48196.
23. Lopez-Bigas N, Audit B, Ouzounis C, Parra G, Guigo R. 2005. Are splicing mutations the most frequent cause of hereditary disease? FEBS Lett 579:1900-1903.
24. Lund E, Dahlberg JE. 1984. True genes for human U1 small nuclear RNA. Copy number, polymorphism, and methylation. J Biol Chem 259:2013-2021.
25. Macke JP, Davenport CM, Jacobson SG, Hennessey JC, Gonzalez-Fernandez F, Conway BP, Heckenlively J, Palmer R, Maumenee IH, Sieving P. 1993. Identification of novel rhodopsin mutations responsible for retinitis pigmentosa: implications for the structure and function of rhodopsin. Am J Hum Genet 53:80-89.
26. Maguire AM, Simonelli F, Pierce EA, Pugh EN Jr, Mingozzi F, Bennicelli J, Banfi S, Marshall KA, Testa F, Surace EM, Rossi S, Lyubarsky A, Arruda VR, Konkle B, Stone E, Sun J, Jacobs J, Dell'osso L, Hertle R, Ma JX, Redmond TM, Zhu X, Hauck B, Zelenaia O, Shindler KS, Maguire MG, Wright JF, Volpe NJ, McDonnell JW, Auricchio A, High KA, Bennett J. 2008. Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Engl J Med 358:2240-2248.
27. Marmor MF, Zrenner E. 1998. Standard for clinical electroretinography (1999 update). International Society for Clinical Electrophysiology of Vision. Doc Ophthalmol 97:143-156.
28. Matsuda T, Cepko CL. 2004. Electroporation and RNA interference in the rodent retina in vivo and in vitro. Proc Natl Acad Sci USA 101:16-22.
29. Mendes HF, van der SJ, Chapple JP, Cheetham ME. 2005. Mechanisms of cell death in rhodopsin retinitis pigmentosa: implications for therapy. Trends Mol Med 11:177-185.
30. Mordes D, Luo X, Kar A, Kuo D, Xu L, Fushimi K, Yu G, Sternberg P Jr, Wu JY. 2006. Pre-mRNA splicing and retinitis pigmentosa. Mol Vis 12:1259-1271.
31. Neidhardt J, Barthelmes D, Farahmand F, Fleischhauer JC, Berger W. 2006. Different amino acid substitutions at the same position in rhodopsin lead to distinct phenotypes. Invest Ophthalmol Vis Sci 47:1630-1635.
32. Nissim-Rafinia M, Kerem B. 2005. The splicing machinery is a genetic modifier of disease severity. Trends Genet 21:480-483.
33. Pagani F, Buratti E, Stuani C, Bendix R, Dork T, Baralle FE. 2002. A new type of mutation causes a splicing defect in ATM. Nat Genet 30:426-429.
34. Pinotti M, Rizzotto L, Balestra D, Lewandowska MA, Cavallari N, Marchetti G, Bernardi F, Pagani F. 2008. U1-snRNA-mediated rescue of mRNA processing in severe factor VII deficiency. Blood 111:2681-2684.
35. Puig O, Bragado-Nilsson E, Koski T, Seraphin B. 2007. The U1 snRNP-associated factor Luc7p affects 5' splice site selection in yeast and human. Nucleic Acids Res 35:5874-5885.
36. Reig C, Alvarez AI, Tejada I, Molina M, Arostegui E, Martin R, Antich J, Carballo M. 1996. New mutation in the 30-AS of intron 4 in the rhodopsin gene associated with autosomal dominant retinitis pigmentosa in a Basque family. Hum Mutat 8:93-94.
37. Roca X, Sachidanandam R, Krainer AR. 2005. Determinants of the inherent strength of human 5′ splice sites. RNA 11:683-698.
38. Sahashi K, Masuda A, Matsuura T, Shinmi J, Zhang Z, Takeshima Y, Matsuo M, Sobue G, Ohno K. 2007. In vitro and in silico analysis reveals an efficient algorithm to predict the splicing consequences of mutations at the 5′ splice sites. Nucleic Acids Res 35:5995-6003.
39. Schneider B, Koppius A, Sedlmeier R. 2007. Use of an exon-trapping vector for the evaluation of splice-site mutations. Mamm Genome 18:670-676.
40. Schuster A, Weisschuh N, Jagle H, Besch D, Janecke AR, Zierler H, Tippmann S, Zrenner E, Wissinger B. 2005. Novel rhodopsin mutations and genotype-phenotype correlation in patients with autosomal dominant retinitis pigmentosa. Br J Ophthalmol 89:1258-1264.
41. Shapiro MB, Senapathy P. 1987. RNA splice junctions of different classes of eukaryotes: sequence statistics and functional implications in gene expression. Nucleic Acids Res 15:7155-7174.
42. Shinohara T, Mulhern ML, Madson CJ. 2008. Silencing gene therapy for mutant membrane, secretory, and lipid proteins in retinitis pigmentosa (RP). Med Hypotheses 70:378-380.
43. Sironi M, Pozzoli U, Cagliani R, Comi GP, Bardoni A, Bresolin N. 2001. Analysis of splicing parameters in the dystrophin gene: relevance for physiological and pathogenetic splicing mechanisms. Hum Genet 109:73-84.
44. Stoilov P, Meshorer E, Gencheva M, Glick D, Soreq H, Stamm S. 2002. Defects in pre-mRNA processing as causes of and predisposition to diseases. DNA Cell Biol 21:803-818.
45. Susani L, Pangrazio A, Sobacchi C, Taranta A, Mortier G, Savarirayan R, Villa A, Orchard P, Vezzoni P, Albertini A, Frattini A, Pagani F. 2004. TCIRG1-dependent recessive osteopetrosis: mutation analysis, functional identification of the splicing defects, and in vitro rescue by U1 snRNA. Hum Mutat 24:225-235.
46. Thanaraj TA, Clark F. 2001. Human GC-AG alternative intron isoforms with weak donor sites show enhanced consensus at acceptor exon positions. Nucleic Acids Res 29:2581-2593.
47. Uchikawa H, Fujii K, Kohno Y, Katsumata N, Nagao K, Yamada M, Miyashita T. 2007. U7 snRNA-mediated correction of aberrant splicing caused by activation of cryptic splice sites. J Hum Genet 52:891-897.
48. Wang GS, Cooper TA. 2007. Splicing in disease: disruption of the splicing code and the decoding machinery. Nat Rev Genet 8:749-761.
49. Wimmer K, Roca X, Beiglbock H, Callens T, Etzler J, Rao AR, Krainer AR, Fonatsch C, Messiaen L. 2007. Extensive in silico analysis of NF1 splicing defects uncovers determinants for splicing outcome upon 50 splice-site disruption. Hum Mutat 28:599-612.
50. Zhuang Y, Weiner AM. 1986. A compensatory base change in U1 snRNA suppresses a 5′ splice site mutation. Cell 46:827-835.